Synlogic Stock Today
| SYBX Stock | USD 1.40 0.04 2.94% |
PerformanceWeak
| Odds Of DistressVery High
|
Synlogic is trading at 1.40 as of the 16th of February 2025; that is 2.94 percent increase since the beginning of the trading day. The stock's open price was 1.36. Synlogic has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 17th of January 2025 and ending today, the 16th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 1st of October 2015 | Category Healthcare | Classification Health Care |
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease and Ginkgo Bioworks, Inc. The company has 11.7 M outstanding shares of which 53.2 K shares are at this time shorted by private and institutional investors with about 2.47 trading days to cover. More on Synlogic
Moving against Synlogic Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Synlogic Stock Highlights
| Old Names | [Ssga Spdr Citi Asia Local Government Bond Etf, SPDR CITI ASIA USD] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsSynlogic can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Synlogic's financial leverage. It provides some insight into what part of Synlogic's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Synlogic (SYBX) is traded on NASDAQ Exchange in USA. It is located in 301 Binney Street, Cambridge, MA, United States, 02142 and employs 6 people. Synlogic is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 16.37 M. Synlogic conducts business under Biotechnology sector and is part of Health Care industry. The entity has 11.7 M outstanding shares of which 53.2 K shares are at this time shorted by private and institutional investors with about 2.47 trading days to cover.
Synlogic currently holds about 106.79 M in cash with (51.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.52, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Synlogic Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Synlogic is $16.37 Million. Over half of Synlogic's outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Synlogic Ownership Details
Synlogic Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| State Street Corp | 2024-09-30 | 10.2 K | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 2.1 K | |
| Bank Of America Corp | 2024-09-30 | 61.0 | |
| Jpmorgan Chase & Co | 2024-09-30 | 16.0 | |
| Ubs Group Ag | 2024-09-30 | 0.0 | |
| Cable Car Capital Llc | 2024-09-30 | 3.3 M | |
| Nea Management Company, Llc | 2024-09-30 | 2.9 M | |
| Vanguard Group Inc | 2024-09-30 | 183 K | |
| Fmr Inc | 2024-09-30 | 166.7 K | |
| Renaissance Technologies Corp | 2024-09-30 | 71.9 K | |
| Geode Capital Management, Llc | 2024-09-30 | 64.2 K |
Synlogic Historical Income Statement
Synlogic Stock Against Markets
Synlogic Corporate Management
| Mylene Perreault | VP Research | Profile | |
| David Hava | Chief Officer | Profile | |
| Mary Dooley | Principal Officer | Profile | |
| Ajay Munshi | Vice Development | Profile | |
| Adam Thomas | Chief Officer | Profile | |
| Michael Jensen | Chief Officer | Profile | |
| Caroline Kurtz | Chief Officer | Profile |
Additional Tools for Synlogic Stock Analysis
When running Synlogic's price analysis, check to measure Synlogic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Synlogic is operating at the current time. Most of Synlogic's value examination focuses on studying past and present price action to predict the probability of Synlogic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Synlogic's price. Additionally, you may evaluate how the addition of Synlogic to your portfolios can decrease your overall portfolio volatility.